Blog

NaviFUS among Final Contestants for Taipei Biotech Award, Makes Progress in Clinical Trials

NaviFUS qualified for entry into the 2019 Taipei Biotech Awards and will present at the prize-winners’ pavilion during the event at Nangang Exhibition Hall. NaviFUS also announced that the safety study for “Focused Ultrasound-induced Blood Brain Barrier (BBB) Disruption in recurrent Glioblastoma patients” has been completed in June, with the case report to be completed in August. The study was conducted at Linkou Chang Gung Memorial Hospital, and none of the subjects had developed any treatment-related side effects. CEO Dr. Arthur Lung stated that the next step would be to continue towards Proof-of-Concept phase study, and he expressed that this project would be a major proponent of NaviFUS’ product line. NaviFUS has also been conducting a safety study for another epilepsy clinical trial recently at Taipei Veterans General Hospital and has completed its first FIH case in June; the study is currently in the stage of continuing to recruit more patients. Also, continuing its previous collaboration with experts in brain tumors and epilepsy from Stanford University…

FUS Foundation visits NaviFUS

We recently had the pleasure of hosting FUS Foundation’s Chairman Neal F. Kassell and Asia Program Director Jessica Lukens, and Council Member Jessica Chao again at NaviFUS. As a focused ultrasound company in Asia, NaviFUS was visited by FUS Foundation as part of its ongoing Asia program. Chairman Jen Chen, CEO Arthur Lung, and CTO Hao-Li Liu gave them a tour of NaviFUS’ facilities and discussed with them the current state of NaviFUS’ operations, potential collaborations and opportunities with FUS Foundation, and landscape of FUS technology in Taiwan and Asia…

The Navifus System has been getting a clinical trial approval for Drug-Resistant Epilepsy in Taiwan

NaviFUS announced that their focus ultrasound system (NaviFUS system) had gotten the clinical trial approval from TFDA for the treatment of drug-resistant epilepsy(DRE). The primary goal of this trial is validation the safety of NaviFUS system using in DRE. Subjects recruiting will start in April…

Navifus has been updating the progression of current trial for rGBM patients

Taiwan-based focused ultrasound manufacturer NaviFUS recently announced the start of its first clinical trial for glioblastoma. To date, three patients have been treated. Researchers at Chang Gung Memorial Hospital are investigating focused ultrasound to induce opening of the blood-brain barrier (BBB) in patients with glioblastoma using optically guided, neuronavigational technology…

Navifus disclosed the early safety data for rGBM patients in 6th ISFU, 2018, USA

The 6th International Symposium on Focused Ultrasound (ISFU) was held in Reston, Virginia, demonstrating the field’s immense progress and the groundbreaking technology’s potential to transform medical therapy worldwide. More than 450 clinicians, scientists, government employees and industry representatives from around the globe gathered October 21–25 to hear 250 presentations on the latest research, including key clinical milestones for neurological indications such as brain tumors, epilepsy, Parkinson’s disease, Alzheimer’s disease, OCD, and depression.
Chief Executive Officer Dr. Lung participate in this symposium and disclosed the initial safety result of FIH trial about ” FUS Open BBB” in rGBM patient at Linkou Chang Gung Memorial Hospital (Taiwan)…

The Navifus System has been getting an IDE qualification and a FIH clinical trial for rGBM patients

The NaviFus Focus Ultrasound System has been getting investigational Device Exemption (IDE) qualification and accepted to execute FIH clinical trial in Q1 for rGBM patients by TFDA Consulting.
It’s a pioneer of brain tumor therapy by using FUS opening BBB temporally in Taiwan’s clinical study. In addition to brain tumors, it is also actively expanding the use of this technology in other central nervous diseases, such as Alzheimer’s disease, epilepsy and so on…

The prototype of NaviFUS System has debuted in the “FUTURE TECH, 2017” Exhibition in Taiwan

“Future Tech, 2017” in Taiwan assembles 109 breakthroughs and industrial applications of forward-looking technology’s research achievements from72 study institutes to participate such as MOST、Science Park、NARLABS、NIH, NSRRC, NCDR… etc. The area including biotechnology and new drugs, Medical materials, electronics and optoelectronics, metal chemicals and innovative materials.
The prototype of Navifus System is also debuted in the exhibition, the system can guide the specific frequency ultrasound to the appropriate position of the temporary opening blood-brain barrier (BBB) and enhance the treatment by helping the drug release.

NaviFUS executives visit FUS Foundation

Executives from NaviFUS, a new focused ultrasound company in Taiwan, visited the Foundation to share information on the status of …

The NaviFUS System received winner of 12th National Innovation Award

Estimation of 98% of current therapeutic agents in the blood stream can not reach brain tumor tissues due to human body’s blood-brain-barrier, causing poor cancer treatment…

The NaviFUS system was reported by Fortune Magazine

By concentrating acoustic energy into the body, we can heat and destroy tumors caused by cancerous cells…